NIKKEI 225
37,780.35 +151.87 (+0.40%) HANG SENG
17,571.33 +286.79 (+1.66%) CRUDE OIL
83.84 +0.27 (+0.32%) GOLD FUTURES
2,346.30 +3.80 (+0.16%) DOW
38,085.80 -375.12 (-0.98%) Bitcoin GBP
51,530.32 +163.48 (+0.32%)
MRK Jan 2025 80.000 put
- Yahoo Finance Video
Merck raises 2024 guidance on cancer drug demand
Shares of Merck & Company (MRK) are trading higher early Thursday after the pharmaceutical giant posted robust sales results in the first quarter, leading the pharmaceutical giant to raise its 2024 outlook. The company's performance was driven by strong demand for its cancer drug Keytruda. Yahoo Finance's Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance. This post was written by Angel Smith
- Benzinga
Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
On Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8 billion, up 9% year-over-year, beating the consensus estimate of $15.2 billion. Excluding the impact of foreign exchange, sales increased 24%. Merck reported adjusted EPS of $2.07, up 48%Y/Y, beating the consensus of $1.88. Merck’s pharmaceutical unit booked $14.01 billion in revenue during the first quarter, up 10% Y/Y. Related: Merck’s $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease. Me
- Zacks
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024. Stock rises in pre-market.
